Sangamo Therapeutics Newsroom

Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know

BenzingaMay 15 23:05

HC Wainwright & Co. : The Sangamo Therapeutics (SGMO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $5.00.

Zhitong FinanceMay 15 22:40

Sangamo Therapeutics Analyst Ratings

BenzingaMay 15 22:35

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target

BenzingaMay 15 22:35

Sangamo Therapeutics Analyst Ratings

BenzingaMar 19 18:30

Sangamo Therapeutics Analyst Ratings

BenzingaMar 15 00:00

RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target

BenzingaMar 14 23:30

Sangamo Therapeutics Analyst Ratings

BenzingaMar 14 00:52

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $3 Price Target

BenzingaFeb 13 01:48

Sangamo Therapeutics Analyst Ratings

BenzingaFeb 13 01:46

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $3 Price Target

BenzingaFeb 6 21:49

Sangamo Therapeutics Analyst Ratings

BenzingaFeb 6 21:46

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $3 Price Target

BenzingaJan 19 19:59

Sangamo Therapeutics Analyst Ratings

BenzingaJan 19 19:57

Wells Fargo Downgrades Sangamo, Cites Removal of Key Year-end Catalyst

Seeking AlphaNov 7, 2023 03:45

HC Wainwright & Co. Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $3

BenzingaNov 7, 2023 00:04

Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight, Announces $1 Price Target

BenzingaNov 6, 2023 21:21

Sangamo Therapeutics Analyst Ratings

BenzingaNov 6, 2023 21:19

RBC Capital Downgrades Sangamo as Biotech Moves to Save Cash

Seeking AlphaNov 4, 2023 03:32

RBC Capital Downgrades Sangamo Therapeutics to Sector Perform, Lowers Price Target to $2

BenzingaNov 3, 2023 18:20